[Reporter’s Notebook] Drug Price Reform: Clearing Away Uncertainty First View original image

In corporate management, nothing is more daunting than uncertainty, not even loss itself. If the scale of a loss can be predicted, countermeasures can be devised, but when it cannot, it becomes difficult to respond proactively. Pharmaceutical companies preparing for the upcoming generic drug price reforms are finding themselves caught in this mire of uncertainty. While the broader direction—lowering drug prices—has been established, the exact timing and specific procedures for the upcoming changes remain shrouded in ambiguity.


The domestic pharmaceutical industry has long been driven by generics. An environment where the prices of generics with identical ingredients could be raised in a relatively stable manner has created a reliable cash cow for many companies. Based on these profits, companies expanded their product lines and scaled up. The structure allowed for outsourcing of production and sales, lowering the entry barrier for small- and medium-sized pharmaceutical firms. It is an undeniable fact that for a long time, many companies released similar drugs and shared prescriptions through sales power.


As a result, generics have become the central backbone of the domestic pharmaceutical industry. Many companies have grown by relying on generic sales rather than developing their own new drugs. This foundation supported employment and production, and sales networks expanded accordingly. This is why a reduction in generic drug prices cannot be dismissed as a mere price adjustment. If this market is shaken, it is inevitable that the shock will extend beyond company profitability to the broader industrial ecosystem.


The rationale behind the government’s push for drug price reform is hard to refute. As the burden on the national health insurance system continues to mount, it is also difficult to disagree with arguments that the pharmaceutical industry should shift its focus from competing by increasing the number of generic items to prioritizing research and development (R&D) as a new driver of future growth.


The core issues are the speed of reform and the presence of buffer measures. Although the second half of the year—the implementation period for the reforms—has begun, it is difficult to predict how gaps will be bridged if the timing of innovative and semi-innovative certification or selection and the timing of price adjustments do not align. It is also unclear how efforts to increase domestic production and raw material self-sufficiency will be reflected in the pricing procedures for existing products. Considering the reality that new drug development requires a long time and enormous costs, it is unrealistic to expect companies whose cash flow from generics suddenly dries up to accelerate R&D investments without a concrete roadmap. Companies need to be able to anticipate which products might be protected for supply stability in order to make informed decisions.



Simply cutting prices will not be enough to reform the management and sales structure centered on generics and to improve the overall health of the industry. Detailed criteria and buffer measures for determining which products to preserve and where to continue investments must be presented as soon as possible. Moreover, efforts to engage with the industry in a more sincere and authentic manner are crucial throughout this process.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing